VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2012

Jun 1, 2012

SEC Form 4/A — Form 4/A

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2012-05-14

Reporting Person: Wysenski Nancy (EVP, Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-05-14	Common Stock	S	179628	$64.27	Disposed	32604	Direct
2012-05-14	Common Stock	S	372	$65.00	Disposed	32232	Direct

Footnotes

F1: Amended to delete a prior footnote that indicated, due to a clerical error by the company, that these transactions were pursuant to a Rule 10b5-1 plan. The Form 144 filed with the SEC in connection with the transactions accurately noted that the sales were not conducted under a Rule 10b5-1 plan.

F2: Open market sales reported on this line occurred at a weighted average price of $64.27 (range $63.90 to $64.82).

F3: Ms. Wysenski undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.